Saturday, 21 November 2026NewsWorldBusinessTech
Latest

HIV Glasgow 2026: Hepatitis B Reactivation Rare After Injectable Switch

Hepatitis B reactivation following a switch to injectable cabotegravir/rilpivirine remains rare, but clinicians must carefully assess protection levels before and after the transition, according to studies presented at HIV Glasgow 2026 and highlighted by EATG.

Cohort studies conducted in Spain and Italy evaluated hepatitis B outcomes after patients transitioned to the long-acting injectable regimen. The investigations found that post-switch reactivation rates were low or non-existent among participants.

While reactivation events were infrequent, the Italian cohort showed a distinct vulnerability regarding baseline immunity. Three vaccinated individuals acquired hepatitis B during the evaluation period. These infections produced no outward symptoms and came to light solely through targeted laboratory screening for hepatitis B core antibody and surface antibody markers.

The findings emphasize that prior vaccination does not automatically guarantee strong protection against hepatitis B following a switch in antiretroviral management. Researchers recommend thorough immunological evaluations to catch silent infections and guard against unexpected reactivation risks in people with HIV.

Clinical guidance outlines specific parameters for managing individuals at risk of reactivation due to immunosuppressive therapy. According to the AASLD, the loss of immune control constitutes reactivation in HBsAg-positive and anti-HBc-positive persons when HBV DNA reaches 10,000 IU/mL or greater if baseline levels are unavailable. Severe consequences include HBV-associated liver failure, which can result in death.

Guidelines from the ASCO recommend that HBsAg-negative and anti-HBc-positive patients undergoing lower-risk immunosuppression be monitored with HBsAg and ALT testing every three months, performing subsequent HBV DNA testing if a hepatitis flare materializes.

Alternatively, close monitoring utilizing HBsAg and HBV DNA every three months is permitted for patients capable of consistent follow-up, allowing immediate antiviral initiation upon reactivation. Prophylactic therapy is typically maintained for 3 to 12 months following immunosuppressive therapy withdrawal, and patients receiving prophylactic antivirals require routine monitoring.

Founded in 1992 following meetings in Berlin, the European AIDS Treatment Group (EATG) emerged during a period of severe stigma and high mortality rates associated with HIV.

Established to challenge what organizers viewed as a failure of national drug research and approval systems to adequately address the epidemic, EATG grew from an initial gathering of 19 individuals into a prominent patient-led network advocating for access to treatment and improved standards of care across Europe.

Readers should consult qualified medical professionals to interpret individual health risks, discuss appropriate screening schedules, and evaluate treatment options. This overview is informational only and does not constitute formal medical advice.